Main competitors
Add to a list
1m. EPS revision 1m. Revenue rev. 4m. EPS revision 4m. Revenue rev. 1y. EPS revision 1y. Revenue rev. Divergence of Estimates Nbr of analysts
21
26
24
27
19
24
20
19
26
22
22
25
21
19
15
18
17
17
16
Average 21
Weighted average by Cap. 23
Other Pharmaceuticals